Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





A Phase I/II Trial of Sapanisertib in Combination with Cabozantinib in ßCatenin-Mutated Hepatocellular Carcinoma

Cancer
April Choi
Liver

Study Description

This phase I/II trial studies the side effects and best dose of sapanisertib when given together with cabozantinib, and to see how well they work in treating patients with liver cancer that has spread from where it first started to other places in the body (metastatic) and contains a mutation (change) in the β-catenin gene. Sapanisertib and cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving sapanisertib and cabozantinib together may work better than giving cabozantinib alone in treating β-catenin-mutated metastatic hepatocellular carcinoma.

Eligibility

  • Patients must have histologically or cytologically confirmed hepatocellular carcinoma, not amendable to curative treatment approach
  • Must be 18 years of age or older
  • For Phase 2, patients must have a ß-catenin mutation
  • Patients who are receiving any other investigational agents
  • Prior exposure to cabozantinib
  • Pregnant women
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.